glp 1 heart failure Early trials of GLP-1 based drugs have shown promising results in patients with with preserved ejection fraction., A new study in JAMA uses real-world evidence that complements these Increased Risk of Heart Failure

SGLT-2=sodium-glucose co-transporter-2

Focal and multifocal neuropathies The primary pathophysiological mechanism underlying focal and multifocal neuropathies is ischemic injury resulting from the occlusion or compromise of the vasa nervorumthe small blood vessels supplying peripheral nerves

Efficacy and safety of mildronate for acute ischemic stroke: a randomized, double-blind, active-controlled phase II multicenter trial

Stanford shares key strategies for maximizing the benefits of GLP-1 medications and ensuring long-term success: Adopt a holistic approach: GLP-1 medications should be part of a comprehensive health plan

Adding complementary treatments (minoxidil, PRP, DHT blockers) may restart progress by addressing mechanisms the peptide doesn't target